• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Inventiva S.A. (Amendment)

    9/25/23 4:35:26 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IVA alert in real time by email
    SC 13D/A 1 sc13da107422iva_09252023.htm AMENDMENT NO. 1 TO SCHEDULE 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 1)1

    Inventiva S.A.

    (Name of Issuer)

    Ordinary Shares, nominal value €0.01 per share

    (Title of Class of Securities)

    46124U107

    (CUSIP Number)

    JAMES KRATKY

    BVF PARTNERS L.P.

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    (415) 525-8890

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    August 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 46124U107

      1   NAME OF REPORTING PERSON  
             
            BIOTECHNOLOGY VALUE FUND, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         4,630,461*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              4,630,461*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            4,630,461*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            8.9%*  
      14   TYPE OF REPORTING PERSON  
             
            PN  

      

    * Includes 451,003 ADSs (as defined below), each of which represents one (1) Share (as defined below).

    2

    CUSIP No. 46124U107

      1   NAME OF REPORTING PERSON  
             
            BVF I GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         4,630,461*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              4,630,461*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            4,630,461*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            8.9%*  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    * Includes 451,003 ADSs, each of which represents one (1) Share.

    3

    CUSIP No. 46124U107

     

      1   NAME OF REPORTING PERSON  
             
            BIOTECHNOLOGY VALUE FUND II, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         3,321,861*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              3,321,861*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,321,861*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            6.4%*  
      14   TYPE OF REPORTING PERSON  
             
            PN  

      

    * Includes 234,997 ADSs, each of which represents one (1) Share.

    4

    CUSIP No. 46124U107

     

      1   NAME OF REPORTING PERSON  
             
            BVF II GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         3,321,861*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              3,321,861*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,321,861*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            6.4%*  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    * Includes 234,997 ADSs, each of which represents one (1) Share.

    5

    CUSIP No. 46124U107

     

      1   NAME OF REPORTING PERSON  
             
            BIOTECHNOLOGY VALUE TRADING FUND OS, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            CAYMAN ISLANDS  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         397,086*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              397,086*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            397,086*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            Less than 1%*  
      14   TYPE OF REPORTING PERSON  
             
            PN  

      

    * Includes 40 ADSs, each of which represents one (1) Share.

    6

    CUSIP No. 46124U107

     

      1   NAME OF REPORTING PERSON  
             
            BVF PARTNERS OS LTD.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            CAYMAN ISLANDS  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         397,086*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              397,086*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            397,086*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            Less than 1%*  
      14   TYPE OF REPORTING PERSON  
             
            CO  

      

    * Includes 40 ADSs, each of which represents one (1) Share.

    7

    CUSIP No. 46124U107

     

      1   NAME OF REPORTING PERSON  
             
            BVF GP HOLDINGS LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         7,952,322*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              7,952,322*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            7,952,322*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            15.4%*  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    * Includes 686,000 ADSs, each of which represents one (1) Share.

    8

    CUSIP No. 46124U107

     

      1   NAME OF REPORTING PERSON  
             
            BVF PARTNERS L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         8,545,499*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              8,545,499*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            8,545,499*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            16.5%*  
      14   TYPE OF REPORTING PERSON  
             
            PN, IA  

      

    * Includes 686,040 ADSs, each of which represents one (1) Share.

    9

    CUSIP No. 46124U107

     

      1   NAME OF REPORTING PERSON  
             
            BVF INC.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         8,545,499*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              8,545,499*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            8,545,499*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            16.5%*  
      14   TYPE OF REPORTING PERSON  
             
            CO  

      

    * Includes 686,040 ADSs, each of which represents one (1) Share.

    10

    CUSIP No. 46124U107

     

      1   NAME OF REPORTING PERSON  
             
            MARK N. LAMPERT  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         8,545,499*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              8,545,499*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            8,545,499*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            16.5%*  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    * Includes 686,040 ADSs, each of which represents one (1) Share.

    11

    CUSIP No. 46124U107

    Explanatory Note: The following constitutes Amendment No. 1 to the Schedule 13D filed by the undersigned (“Amendment No. 1”). This Amendment No. 1 amends the Schedule 13D as specifically set forth herein and is being filed to report, among other things, a change in the percentage of the outstanding number of Shares owned by the Reporting Persons solely due to an increase in the number of Shares outstanding.

    Item 1.Security and Issuer.

    Item 1 is hereby amended and restated to read as follows:

    This statement relates to the Ordinary Shares, nominal value €0.01 per share (the “Shares”), of Inventiva S.A., a corporation organized under the laws of France (the “Issuer”) and to American Depositary Shares of the Issuer (“ADSs”), each of which represents one Share. The address of the principal executive offices of the Issuer is 50 rue de Dijon, 21121 Daix, France.

    Item 3.Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended and restated to read as follows:

    The securities of the Issuer purchased by BVF, BVF2 and Trading Fund OS were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) in open market transactions, except as otherwise noted. The aggregate purchase price of the 4,179,458 Shares owned directly by BVF is approximately $26,042,201, including brokerage commissions. The aggregate purchase price of the 451,003 ADSs owned directly by BVF is approximately $6,244,319, including brokerage commissions. The aggregate purchase price of the 3,086,864 Shares owned directly by BVF2 is approximately $19,101,307, including brokerage commissions. The aggregate purchase price of the 234,997 ADSs owned directly by BVF2 is approximately $3,149,991, including brokerage commissions. The aggregate purchase price of the 397,046 Shares owned directly by Trading Fund OS is approximately $2,484,759, including brokerage commissions. The aggregate purchase price of the 40 ADSs owned directly by Trading Fund OS is approximately $311, including brokerage commissions. The aggregate purchase price of the 196,091 Shares held in the Partners Managed Account is approximately $1,090,300, including brokerage commissions.

    Item 5.Interest in Securities of the Issuer.

    Items 5(a) and (c) are hereby amended and restated to read as follows:

    (a)       The aggregate percentage of Shares reported owned by each person named herein is based on 51,752,807 Shares outstanding, which is the Issuer’s expected total number of Shares outstanding as of September 5, 2023, as reported in Exhibit 99.3 to the Issuer’s Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on August 31, 2023.

    As of the date hereof, (i) BVF beneficially owned 4,630,461 Shares, including 451,003 Shares underlying ADSs held by it, representing percentage ownership of approximately 8.9% of the Shares outstanding, (ii) BVF2 beneficially owned 3,321,861 Shares, including 234,997 Shares underlying ADSs held by it, representing percentage ownership of approximately 6.4% of the Shares outstanding, (iii) Trading Fund OS beneficially owned 397,086 Shares, including 40 Shares underlying ADSs held by it, representing percentage ownership of less than 1% of the Shares outstanding, and (iv) 196,091 Shares were held in the Partners Managed Account, representing percentage ownership of less than 1% of the Shares outstanding.

    12

    CUSIP No. 46124U107

    BVF GP, as the general partner of BVF, may be deemed to beneficially own the 4,630,461 Shares beneficially owned by BVF, representing percentage ownership of approximately 8.9% of the Shares outstanding.

    BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 3,321,861 Shares beneficially owned by BVF2, representing percentage ownership of approximately 6.4% of the Shares outstanding.

    Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 397,086 Shares beneficially owned by Trading Fund OS, representing percentage ownership of less than 1% of the Shares outstanding.

    BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 7,952,322 Shares beneficially owned in the aggregate by BVF and BVF2, representing percentage ownership of approximately 15.4% of the Shares outstanding.

    Partners, as the investment manager of BVF, BVF2, Trading Fund OS and the Partners Managed Account and the sole member of Partners OS, may be deemed to beneficially own the 8,545,499 Shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and held in the Partners Managed Account, representing percentage ownership of approximately 16.5% of the Shares outstanding.

    BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 8,545,499 Shares beneficially owned by Partners, representing percentage ownership of approximately 16.5% of the Shares outstanding.

    Mr. Lampert, as a director and officer of BVF Inc. may be deemed to beneficially own the 8,545,499 Shares beneficially owned by BVF Inc., representing percentage ownership of approximately 16.5% of the Shares outstanding.

    (c)       None of the Reporting Persons have entered into any transactions in the securities of the Issuer during the past sixty days.

     

    13

    CUSIP No. 46124U107

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: September 25, 2023

    BIOTECHNOLOGY VALUE FUND, L.P.   BIOTECHNOLOGY VALUE TRADING FUND OS LP
           
    By: BVF I GP LLC, its general partner   By: BVF Partners L.P., its investment manager
          By: BVF Inc., its general partner
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF I GP LLC      
          BVF GP HOLDINGS LLC
    By: /s/ Mark N. Lampert    
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            Chief Executive Officer
             
    BIOTECHNOLOGY VALUE FUND II, L.P.    
          BVF PARTNERS L.P.
    By: BVF II GP LLC, its general partner    
          By: BVF Inc., its general partner
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF II GP LLC      
          BVF INC.
    By: /s/ Mark N. Lampert    
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF PARTNERS OS LTD.      
          /s/ Mark N. Lampert
    By: BVF Partners L.P., its sole member   MARK N. LAMPERT
    By: BVF Inc., its general partner    
             
    By:

    /s/ Mark N. Lampert

       
      Mark N. Lampert    
      President      

    14

     

    Get the next $IVA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IVA

    DatePrice TargetRatingAnalyst
    2/21/2025$10.00Buy
    TD Cowen
    11/12/2024$3.00Neutral
    UBS
    10/27/2023$12.00Buy
    Canaccord Genuity
    5/31/2023$11.00Buy
    ROTH MKM
    5/19/2023Sell → Buy
    Societe Generale
    3/17/2023$27.00Buy
    Stifel
    11/15/2022Buy → Sell
    Societe Generale
    11/22/2021$40.00 → $42.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Inventiva with a new price target

    TD Cowen initiated coverage of Inventiva with a rating of Buy and set a new price target of $10.00

    2/21/25 8:15:44 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Inventiva with a new price target

    UBS initiated coverage of Inventiva with a rating of Neutral and set a new price target of $3.00

    11/12/24 7:43:33 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Inventiva with a new price target

    Canaccord Genuity initiated coverage of Inventiva with a rating of Buy and set a new price target of $12.00

    10/27/23 7:43:43 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

    Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that Jason Campagna, MD, PhD, President of R&D and Chief Medical Officer, and David Nikodem, PhD, Vice President of US Operations will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference. The conference is being held from August 12-14, 2025, at the InterContinental Hotel in Boston, Massachusetts. During the fireside chat, Drs. Campagna and Nikodem wil

    8/11/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

    Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH"), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of June 30, 2025: Cash:

    7/31/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva Reports Preliminary 2025 First-Half Financial Information¹

    Cash and cash equivalents at €122.1 million and €24.6 million in short-term deposits2 as of June 30, 2025Revenues of €4.5 million recorded in H1 2025 Daix (France), New York City (New York, United States), July 29, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported certain preliminary financial results for the first half of 2025, including its cash, cash equivalents, and revenues. Preliminary Financial Results As of June 30, 2025, the Company's cash and cash equivalents amounted

    7/29/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    SEC Filings

    View All

    SEC Form 6-K filed by Inventiva S.A.

    6-K - Inventiva S.A. (0001756594) (Filer)

    7/29/25 4:52:39 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Inventiva S.A.

    6-K - Inventiva S.A. (0001756594) (Filer)

    7/9/25 4:29:45 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Inventiva S.A.

    6-K - Inventiva S.A. (0001756594) (Filer)

    7/7/25 4:58:33 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Financials

    Live finance-specific insights

    View All

    Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

    Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the "Structured Financi

    5/5/25 2:30:00 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva reports its 2024 full year results and provides a business update

    Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c

    3/26/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

    Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder

    3/19/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Leadership Updates

    Live Leadership Updates

    View All

    Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

    Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MDMartine Zimmermann, PharmD, joins as Executive Vice President of Regulatory Affairs and Quality AssuranceThese key leadership appointments underscore Inventiva's commitment to long-term growth and operational excellence, with topline results from NATiV3 on track for the second half of 2026 Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic

    7/9/25 4:05:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

    Daix (France), New York City (New York, United States), June 10, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the appointment of Renée Aguiar-Lucander to its Board of Directors. The appointment was approved by shareholders at the recent Company's Annual General Meeting. Mark Pruzanski, Chairman of Inventiva: "We are thrilled to welcome Renée to the Board at this pivotal moment in Inventiva's journey. Her exceptional track record in our industry speaks for itself and will be

    6/10/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

    Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024.   Proceeds from the completed first tranche to be primarily used to advance Inventiva's Phase III, NATiV3 clinical trial evaluating lanifibranor in patients with MASH.   Appointment of Mark Pruzanski as new Chairman of the Board of Directors and Srinivas Akkaraju as new member of the Board of Directors. Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinica

    12/16/24 2:30:00 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

    SC 13D/A - Inventiva S.A. (0001756594) (Subject)

    10/21/24 9:00:40 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

    SC 13D/A - Inventiva S.A. (0001756594) (Subject)

    10/21/24 8:54:43 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

    SC 13D/A - Inventiva S.A. (0001756594) (Subject)

    7/19/24 4:30:23 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care